Rodrigues, Maria de Lourdes VeroneseFelipe Crosta, Daniela Pereira Da SilvaSoares, Christiane Pienna [UNESP]Deghaide, Neifi Hassam SaloumDuarte, Roberta [UNESP]Sakamoto, Fabiano S.Furtado, João Marcello FortesPaula, Jayter SilvaDonadi, Eduardo AntonioSoares, Edson Garcia2014-05-272014-05-272009-03-01Journal of Glaucoma, v. 18, n. 3, p. 197-200, 2009.1057-0829http://hdl.handle.net/11449/70941PURPOSE: Subclinical inflammation may be observed in patients using topical antiglaucomatous drugs. The objective of this study was to investigate inflammation in conjunctiva of glaucoma patients using prostaglandin analogs, by the detection of an immunogenetic marker (HLA-DR) and compare the effect of 3 different drugs: latanoprost, bimatoprost, and travoprost in the induction of this inflammation. SUBJECTS AND METHODS: Thirty-three patients with primary open-angle glaucoma were evaluated without and with prostaglandin analogs topical therapy. Imprints of conjunctival cells were obtained, fixed on glass slides, and prepared for immunohistochemical analysis. RESULTS: Before the use of prostaglandin analogs, 4 of the 33 patients evaluated presented expression of HLA-DR in the conjunctiva (mild). After 1 month on prostaglandin analog treatment, all but 1 patient presented HLA-DR staining. HLA-DR expression of these 32 patients was scored as mild (19 patients), medium (11 patients), or intense (2 patients). The differences were statistically significant both when the presence and the increased expression of HLA-DR were considered (P<0.001). When the 3 different groups were analyzed (latanoprost, bimatoprost, and travoprost) no statistically significant difference was found (P=0.27). CONCLUSIONS: The use of prostaglandin analogs eye drops provokes a subclinical inflammatory reaction, observed by HLA-DR expression, even after a short period of treatment, independently of the class of the prostaglandin analogs used. © 2009 Lippincott Williams & Wilkins, Inc.197-200engConjunctival in.ammationGlaucoma treatmentHLA-DRProstaglandin analogbimatoprostHLA DR antigenlatanoprosttravoprostamideantihypertensive agentbiological markercloprostenoldrug derivativeprostaglandin Fadultagedantigen expressionclinical articleconjunctivaconjunctivitiscontrolled studydrug effectfemalehumanhuman cellimmunohistochemistrymaleopen angle glaucomapriority journalchemically induced disorderenzyme immunoassaymetabolismmiddle agedtopical drug administrationAdministration, TopicalAgedAged, 80 and overAmidesAntihypertensive AgentsBiological MarkersCloprostenolConjunctivitisFemaleGlaucoma, Open-AngleHLA-DR AntigensHumansImmunoenzyme TechniquesMaleMiddle AgedProstaglandins F, SyntheticArtigo10.1097/IJG.0b013e31818153f4Acesso restrito2-s2.0-6564913693017680252903736690000-0003-1740-7360